# Study to Evaluate the Immunogenicity and Safety of a Heterologous Vaccine Regimen Against Ebola

> **NCT04186000** · PHASE2 · COMPLETED · sponsor: **Universiteit Antwerpen** · enrollment: 699 (actual)

## Conditions studied

- Ebola Virus Disease

## Interventions

- **BIOLOGICAL:** Ad26.ZEBOV vaccine

## Key facts

- **NCT ID:** NCT04186000
- **Lead sponsor:** Universiteit Antwerpen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-18
- **Primary completion:** 2020-04-25
- **Final completion:** 2022-10-12
- **Target enrollment:** 699 (ACTUAL)
- **Last updated:** 2023-01-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04186000

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04186000, "Study to Evaluate the Immunogenicity and Safety of a Heterologous Vaccine Regimen Against Ebola". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04186000. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*